Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Retrospective Review of the Use of Oral Chemotherapy Drugs for Patients with Metastatic Kidney Cancer
Nathan M. Kawamura, PharmD, BCOP, Sara Griesbach , PharmD, BCPS, BCACP, Sue Wilhelm, RPh, BCPS, Richard Mercier, MD
Comparing Grade 4 Neutropenia Associated with Pegfilgrastim Administered via the Onpro Device versus Manual Injection with a Prefilled Syringe
Impact of Pharmacist-Driven Educational Intervention on Documentation of Bowel Function Assessment in Patients with Cancer Who Are Using Opioids
Elizabeth R. Pritchard, PharmD, BCOP, J. Aubrey Waddell, PharmD, FAPhA, BCOP, Brad J. Crane, PharmD, BCPS, Amy M. Porter, PharmD, Susan Roberts, PharmD, Danielle M. Yates, PharmD, Angelia M. Thomas, MT (ASCP)
Oral chemotherapeutic agents have been available for many years, and were traditionally cytotoxic drugs, such as cyclophosphamide, methotrexate, and mercaptopurine. In recent years, oral anticancer medications are being used more often in many types of cancer.
Retrospective Analysis of Probiotic Effectiveness in Patients with Acute Myeloid Leukemia or Patients Undergoing Transplant Who Are Receiving Chemotherapy
It is well-known that patients with acute myeloid leukemia (AML) who receive induction and reinduction chemotherapy and any patients undergoing hematopoietic stem-cell transplant (HSCT) are at high risk for infections and prolonged hospital stays. Intensive chemotherapy regimens used in these settings cause patients to be neutropenic for prolonged durations.
Pain is one of the most feared symptoms of cancer, with uncontrolled pain being the most frequently reported symptom in hospitalized patients with cancer. As cancer stage progresses, the pain intensity and incidence increase, with cancer pain reported in 62% to 86% of patients with advanced disease.
Page 1 of 5
Results 1 - 10 of 42
Results 1 - 10 of 42